Unique ID issued by UMIN | UMIN000053309 |
---|---|
Receipt number | R000060850 |
Scientific Title | The effect of the test diet on the absorption and excretion of water and electrolytes in the body in a heatstroke dehydration model - A randomized, double-blind, placebo-controlled, two-periods cross-over comparative trial - |
Date of disclosure of the study information | 2024/01/15 |
Last modified on | 2024/05/21 14:19:51 |
The effect of the test diet on the absorption and excretion of water and electrolytes in the body under a heatstroke dehydration model
The effect of the test diet on the absorption and excretion of water and electrolytes in the body under a heatstroke dehydration model
The effect of the test diet on the absorption and excretion of water and electrolytes in the body in a heatstroke dehydration model
- A randomized, double-blind, placebo-controlled, two-periods cross-over comparative trial -
The effect of the test diet on the absorption and excretion of water and electrolytes in the body in a heatstroke dehydration model
- A placebo-controlled, double-blind, cross-over trial-
Japan |
Dehydration, heat stroke
Adult |
Others
NO
The aim of this study is to compare the absorption and excretion rate of water by intake of the test diet using a heatstroke dehydration model induced by sauna stress in male subjects aged over 20 years.
The secondary endpoint is to compare the electrolytes similarly.
Efficacy
Changes in body weight after sauna stress
Hematologic test
Blood biochemistry test
Urinalysis
Physiological test
Fractional Excretion of Sodium
Electrolyte balance
Water balance
Physical symptoms
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
The test diet of the equal amount of body weight loss after sauna stress is separately given by three times.
The placebo diet of the equal amount of body weight loss after sauna stress is separately given by three times.
20 | years-old | <= |
Not applicable |
Male
1. Males aged 20 or older on the day of consent acquisition.
2. Body weight is over 50 kg.
3. Percent Body fat is below or equal to 25 percent.
4. Those who can use smartphones or PC to record a digital diary.
5. Received a sufficient explanation for the study objective, and voluntarily joined the study with the agreement to informed consent.
1. Those who regularly use foods or supplements with functional health claims that may affect the study outcome three times or more a week and cannot stop them from the time of consent acquisition (e.g., health foods containing capsaicin, spices, or other strong stimulants that have effects such as improving blood flow, increasing body temperature, or inducing sweating).
2. Currently receiving drug therapy (however as-needed medication is acceptable.) .
3. Heavy alcohol drinker with a habit of drinking over an average of 40 g/day per week.
4. Those who have difficulty with blood sampling.
5. Those who have a tattoo.
6. Those who feel difficulty with sweating in a sauna bath.
7. Subjects without body weight fluctuation due to sweating.
8. Those who can't enter a sauna bath for ten minutes three times.
9. Those who can't enter an one person sauna bath due to claustrophobia.
10. Those who have a scar for a burn injury in a wide area on the body.
11. Those who have severe diseases or a history of severe diseases in the heart, liver, kidney, or digestive organs.
12. Those who have allergies to drugs or foods.
13. Those who are participating in clinical studies of other drugs or health foods, within 4 weeks after the end of the study, or who plan to participate in other clinical studies after consenting to participate in the study.
14. Those who donated blood components or whole blood of 200 mL within one month before the start of the study.
15. Those who have blood donation above 400 mL within three months before the start of the study.
16. Those whose total blood collection volume, including the planned volume for the study and the volume collected in the previous 12 months, exceeds 1200 mL prior to the initiation of the study.
17. Those who are deemed unsuitable for participation in the study by the principal investigator or the sub-investigator.
20
1st name | Yukinori |
Middle name | |
Last name | Saeki |
GOSHU YAKUHIN CO., LTD.
Research and Development Department
939-8201
1-1-5, Hanazono-cho, Toyama 939-8201,JAPAN
076-424-2661
saeki@goshu.co.jp
1st name | Yoshitada |
Middle name | |
Last name | Hira |
IMEQRD Co., Ltd
Planning and Sales Department
104-0061
6-2-1 Ginza Chuo-ku Tokyo Japan
03-6704-5968
https://imeqrd.co.jp/
clinical-trial@imeqrd.co.jp
GOSHU YAKUHIN CO., LTD.
GOSHU YAKUHIN CO., LTD.
Profit organization
Suda Clinic institutional review board
2-8-14,Takadanobaba,Shinjyuku,Tokyo
03-6704-5968
jimukyoku@imeqrd.co.jp
NO
2024 | Year | 01 | Month | 15 | Day |
Unpublished
Completed
2023 | Year | 12 | Month | 18 | Day |
2023 | Year | 12 | Month | 26 | Day |
2024 | Year | 01 | Month | 16 | Day |
2024 | Year | 02 | Month | 28 | Day |
2024 | Year | 01 | Month | 10 | Day |
2024 | Year | 05 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060850